About this talk
Value-based drug pricing helps us to understand the maximum amount of money we’re willing to pay for treatments that could benefit patients and save lives. The idea is simple: We should pay more for drugs that do more and generate more life, and we should pay less for drugs that do less. However, what happens when the value-based price for a tremendous drug is legitimately in the millions of dollars?
Healthcare economist Amitabh Chandra acknowledges that although value-based pricing is an appealing idea, it isn’t the right model if we want to be sure that the amazing drugs of the future—from revolutionary cures to regenerative medicines—are accessible and affordable for all. Tune in to Amitabh’s 2017 TEDMED Talk to learn more about the innovative models he believes could help to ensure that everyone is able to benefit from the lifesaving drugs of tomorrow.
About Amitabh Chandra
See more
Amitabh Chandra is a leading health care economist and professor at Harvard Business School and the Harvard Kennedy School of Government. His research focuses on the unique effects that economic factors have on health care, from the price of medicine to the development of new treatments. He is particularly known for his work on racial disparities in health care. Amitabh examines how different groups of people receive different levels of care and how to create a more equitable system. His research has led him to testify before the U.S. Senate and the U.S. Commission on Civil Rights, where he advocates for fairer health policies. In addition to his academic roles, he is the Director of Health Policy Research at the Harvard Kennedy School. He also serves as Chair Editor of the Review of Economics and Statistics and is an elected member of the National Academy of Medicine. His work has received extensive media coverage and is critical for understanding some of the most complex challenges facing the health care system today.
